Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) CFO David Joseph Topper sold 11,626 shares of the stock in a transaction on Tuesday, September 24th. The stock was sold at an average price of $9.48, for a total transaction of $110,214.48. Following the sale, the chief financial officer now owns 158,374 shares of the company’s stock, valued at approximately $1,501,385.52. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Arcutis Biotherapeutics Price Performance
Shares of NASDAQ:ARQT opened at $9.36 on Friday. The company has a quick ratio of 8.19, a current ratio of 8.46 and a debt-to-equity ratio of 1.09. The company has a market cap of $1.09 billion, a P/E ratio of -3.19 and a beta of 1.18. Arcutis Biotherapeutics, Inc. has a 52 week low of $1.76 and a 52 week high of $13.17. The company has a 50-day moving average price of $9.83 and a 200 day moving average price of $9.52.
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.06. The firm had revenue of $30.86 million for the quarter, compared to the consensus estimate of $31.00 million. Arcutis Biotherapeutics had a negative return on equity of 145.41% and a negative net margin of 150.51%. During the same period in the previous year, the business earned ($1.16) earnings per share. Research analysts predict that Arcutis Biotherapeutics, Inc. will post -1.56 earnings per share for the current year.
Analyst Ratings Changes
View Our Latest Stock Analysis on Arcutis Biotherapeutics
Hedge Funds Weigh In On Arcutis Biotherapeutics
Institutional investors and hedge funds have recently made changes to their positions in the stock. Cape Investment Advisory Inc. acquired a new stake in shares of Arcutis Biotherapeutics in the fourth quarter valued at about $26,000. Cantor Fitzgerald L. P. purchased a new stake in shares of Arcutis Biotherapeutics during the 4th quarter worth approximately $33,000. Victory Capital Management Inc. acquired a new stake in shares of Arcutis Biotherapeutics in the 4th quarter worth approximately $34,000. CWM LLC increased its stake in Arcutis Biotherapeutics by 6,740.0% in the 2nd quarter. CWM LLC now owns 4,104 shares of the company’s stock valued at $38,000 after purchasing an additional 4,044 shares in the last quarter. Finally, Ameritas Investment Partners Inc. raised its holdings in Arcutis Biotherapeutics by 55.2% during the first quarter. Ameritas Investment Partners Inc. now owns 7,871 shares of the company’s stock worth $78,000 after purchasing an additional 2,800 shares during the last quarter.
Arcutis Biotherapeutics Company Profile
Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.
Further Reading
- Five stocks we like better than Arcutis Biotherapeutics
- What Investors Need to Know About Upcoming IPOs
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- How to Invest in Blue Chip Stocks
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- P/E Ratio Calculation: How to Assess Stocks
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.